TL;DR:
- Asep Medical Holdings Inc. achieved a crucial milestone with the approval of its AI-based sepsis diagnostic technology, Sepset, in the United States.
- The US patent, exclusively licensed to Sepset Biosciences Inc., validates the innovative approach to sepsis diagnosis, impacting a population of 332 million.
- This achievement follows European and Australian patent successes, expanding the technology’s reach to approximately 400 million people.
- The patent approval paves the way for formal clinical studies in the US, positioning Sepset for FDA approval and global deployment.
- Sepset revolutionizes sepsis diagnosis with a swift blood-based gene expression assay, offering results in 60-90 minutes compared to 8-36 hours with current tools.
- CEO Dr. Robert E. W. Hancock emphasizes the strategic importance of patents in the biotechnology sector, strengthening the company’s position in the market.
Main AI News:
In a significant milestone, Asep Medical Holdings Inc. has achieved a major breakthrough with the approval of its cutting-edge AI-based sepsis diagnostic technology, known as Sepset, in the United States. The company recently received official confirmation from its legal team regarding the successful patent approval for US Patent Application No. 16/279788, a development that covers a vast population of 332 million Americans. This accomplishment comes on the heels of the Company’s triumph in securing European and Australian patents in November 2022, collectively extending its reach to approximately 400 million individuals.
The US patent, officially granted on August 18, 2023, is exclusively licensed to Asep Inc.’s subsidiary, Sepset Biosciences Inc. It underscores the exceptional and pioneering approach that Asep Medical Holdings Inc. has taken in the realm of sepsis diagnosis, a condition responsible for more than 11 million fatalities globally each year. Sepset, a blood-based gene expression assay, was meticulously developed under the leadership of renowned UBC microbiologist and Asep Inc.’s Founder, Chair & CEO, Dr. Robert E. W. Hancock. This groundbreaking test not only facilitates early risk assessment for sepsis but also expedites targeted treatment strategies. It is worth noting that sepsis is a leading cause of mortality in individuals afflicted with severe COVID-19.
Moreover, these patents provide a firm foundation for the company’s future endeavors, especially as the Sepset test is in advanced stages of development and gearing up for formal clinical 510(k) studies in the United States. With the SepsetER signature having already demonstrated its effectiveness through validation and refinement in over 700 sepsis and severe COVID-19 cases to date, the company is now preparing to replicate this success in a formal trial setting. In the realm of diagnostics, the 510(k) pathway entails a single clinical study that, if successful, will culminate in approval from the US Food & Drug Administration (FDA). Once granted, the test will be made available for use in emergency rooms and intensive care units worldwide, equipping healthcare professionals with the ability to make well-informed decisions about patient care, ultimately leading to improved prognoses and higher survival rates.
The Sepset test is a groundbreaking innovation that detects the dysfunctional immune responses characteristic of sepsis from the moment patients enter the emergency room. This blood-based gene expression assay is designed for straightforward implementation using standard equipment found in most hospital laboratories, providing results within a remarkably swift timeframe of 60-90 minutes. In contrast, current diagnostic tools necessitate waiting times ranging from 8 to 36 hours, often resulting in delayed initiation of treatment. Sepset’s primary objective is to empower physicians to swiftly anticipate the severity of the disease, triggering immediate and tailored patient interventions.
CEO Dr. Robert E. W. Hancock emphasized the critical importance of patents in the biotechnology sector, stating, “Patents are the lifeblood of biotechnology companies like ours. This new patent in the US once again validates the novelty of our technology in major markets, which now represents over 700 million people.”
Conclusion:
Asep Medical Holdings Inc.’s successful US patent approval for Sepset signifies a major step forward in the battle against sepsis. The exclusive licensing and the potential for rapid diagnostics could revolutionize patient care, and this achievement strengthens the company’s position in the biotechnology market, appealing to a substantial global population.
